Johnson & Johnson Phase 1/2 are in

64% of Participants 18-55 yrs old (cohort 1)

Experienced Systemic Adverse Events !!

58% of Participants 18-55 yrs old 

Experienced Local Adverse events 

https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf